AHA Names Top Advances in Cardiovascular Disease Research for 2023

Every year, researchers gain a deeper understanding of the pathways that lead to cardiovascular disease and how to better prevent and treat heart disease and stroke.

In 2023, investigators made important strides toward improving and extending the lives of people affected by these conditions, along with potentially lowering the burden of disease with therapies and strategies that hold promise for prevention.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association. 

Read the full article by the American Heart Association: AHA Names Top Advances in Cardiovascular Disease Research for 2023

Related Content

Dec. 15, 2023

Science’s 2023 Breakthrough of the Year: Weight Loss Drugs with a Real Shot at Fighting Obesity
Presented by the lead author Mikhail Kosiborod, MD, the STEP-HFpEF trial is recognized by Science Magazine as Breakthrough of the Year throughout all science.
Aug. 25, 2023

U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients
Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.
Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.